• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2012年德国62家医院全国性样本中新兴细菌病原体的一日点患病率及与2010年一日点患病率结果的比较。

One-day point prevalence of emerging bacterial pathogens in a nationwide sample of 62 German hospitals in 2012 and comparison with the results of the one-day point prevalence of 2010.

作者信息

Wegner Christian, Hübner Nils-Olaf, Gleich Sabine, Thalmaier Ulrike, Krüger Colin M, Kramer Axel

机构信息

Institute of Hygiene and Environmental Medicine, University Medicine Greifswald, Ernst-Moritz-Arndt University, Greifswald, Germany.

出版信息

GMS Hyg Infect Control. 2013 Apr 29;8(1):Doc12. doi: 10.3205/dgkh000212. eCollection 2013.

DOI:10.3205/dgkh000212
PMID:23967398
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3746607/
Abstract

BACKGROUND

Antibiotic resistance of bacterial pathogens is an emerging problem worldwide. To combat multidrug resistant organisms (MRDOs) networks of care providers have been established in all states in Germany. The HICARE-network, a project to combat MRDOs, founded by the Federal Ministry of Education and Research, has published data from 2010 of a voluntary, German-wide, multicenter point-prevalence survey in 2011 conducted in collaboration with the German Society of Hospital Hygiene. The aim of the present survey was the re-evaluation of the situation in 2012.

METHOD

The survey was conducted as a voluntary, anonymous, point-prevalence in May 2012 using routine data of microbiological diagnostics of the hospitals. As in the former survey of 2010 it was differentiated between primary, secondary and tertiary care hospitals and only data from intensive care units, surgical and medical wards were collected. Based on the survey form used in 2010, an updated version was used including more pathogens and corrected issues observed in the former survey. Methicillin-resistant Staphylococcus aureus (MRSA) (total as well as separated in hospital-acquired (HA), community-acquired (CA) and lifestock-associated (LA) MRSA), vancomycin resistant Staphylococcus aureus (VRSA/GRSA), vancomycin resistant Enterococcus faecalis resp. Enterococcus faecium (VR-E. faecalis resp. VR-E. faecium), extended-spectrum-beta-lactamase-building (ESBL) E. coli (ESBL-EC) and Klebsiella pneumoniae (ESBL-KP), multiresistant Acinetobacter spp. (MAB), multiresistant Pseudomonas spp. (MRP), carbapenemase-producing Enterobacteriaceae (CRE) as well as Clostridium difficile (CD) infections and severe infections requiring ICU-treatment were included in the survey along with additional data on screening strategy, the equipment with infection control staff and possible confounders.

RESULTS

Out of 1,550 hospitals asked to participate, 62 returned data (4%). Data from 56 hospitals including primary (26), secondary (20) and tertiary (10) care hospitals were analyzable (3.6%). The most frequently reported organisms were MRSA 1.53% [CI95: 1.32-1.75], followed by CDAD 1.30% [CI95: 1.11-1.50], ESBL-EC 0.97% [CI95: 0.80-1.14], and ESBL-KP 0.27% [CI95: 0.18-0.36], regardless of the level of care. Prevalence of MRDOs depended on the level of care and on the type of ward, as expected. Overall prevalence was highest on intensive care wards, and prevalences were remarkably high on medical wards compared to surgical wards. All tertiary care providers employed their own infection control nurse, while only ~70% of the secondary and primary care hospitals did. Surprisingly, in two of the ten participating tertiary care providers neither an internal nor an external infection control doctor was available.

DISCUSSION

With more than 13,000 patients in 56 hospitals distributed all over Germany, the survey included more than three times as many patients as the first survey and therefore not only adds valuable information about the epidemiology of emerging nosocomial pathogens, but also helps to raise awareness of the problem of antibacterial resistance in Germany. The prevalences reported seem to be comparable to the results of the former survey and of other surveys published. Some hospitals reported to have no infection control personnel available at all. This statement is in line with another survey published in this issue.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b8/3746607/436905923fb1/HIC-08-12-t-007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b8/3746607/3ff2f5ce2c8f/HIC-08-12-t-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b8/3746607/b2e7a3027624/HIC-08-12-t-002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b8/3746607/8d7054436f8e/HIC-08-12-t-003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b8/3746607/6c0b4a4977de/HIC-08-12-t-004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b8/3746607/37210afd6dd1/HIC-08-12-t-005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b8/3746607/b85b76fe6d8e/HIC-08-12-t-006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b8/3746607/436905923fb1/HIC-08-12-t-007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b8/3746607/3ff2f5ce2c8f/HIC-08-12-t-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b8/3746607/b2e7a3027624/HIC-08-12-t-002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b8/3746607/8d7054436f8e/HIC-08-12-t-003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b8/3746607/6c0b4a4977de/HIC-08-12-t-004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b8/3746607/37210afd6dd1/HIC-08-12-t-005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b8/3746607/b85b76fe6d8e/HIC-08-12-t-006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b8/3746607/436905923fb1/HIC-08-12-t-007.jpg
摘要

背景

细菌病原体的抗生素耐药性是全球范围内一个新出现的问题。为应对多重耐药菌,德国所有州都建立了医疗服务提供者网络。由联邦教育与研究部发起的抗击多重耐药菌项目HICARE网络,公布了2010年与德国医院卫生协会合作在德国范围内开展的一项自愿性多中心现患率调查的数据。本次调查的目的是重新评估2012年的情况。

方法

本次调查于2012年5月以自愿、匿名的方式进行现患率调查,采用医院微生物诊断的常规数据。与2010年的前一次调查一样,区分了一级、二级和三级护理医院,仅收集重症监护病房、外科和内科病房的数据。基于2010年使用的调查问卷,使用了一个更新版本,包括更多病原体,并纠正了前一次调查中发现的问题。耐甲氧西林金黄色葡萄球菌(MRSA)(包括医院获得性(HA)、社区获得性(CA)和家畜相关(LA)MRSA的总数及分类)、耐万古霉素金黄色葡萄球菌(VRSA/GRSA)、耐万古霉素粪肠球菌或屎肠球菌(VR-E. faecalis或VR-E. faecium)、产超广谱β-内酰胺酶(ESBL)的大肠埃希菌(ESBL-EC)和肺炎克雷伯菌(ESBL-KP)、多重耐药不动杆菌属(MAB)、多重耐药假单胞菌属(MRP)、产碳青霉烯酶肠杆菌科细菌(CRE)以及艰难梭菌(CD)感染和需要重症监护治疗的严重感染均纳入调查,同时还包括关于筛查策略、感染控制人员配备及可能混杂因素的其他数据。

结果

在被邀请参与的1550家医院中,62家返回了数据(4%)。来自56家医院的数据可进行分析,其中包括一级护理医院26家、二级护理医院20家、三级护理医院10家(3.6%)。最常报告的病原体是MRSA,为1.53% [95%置信区间:1.32 - 1.75],其次是艰难梭菌感染相关性腹泻(CDAD),为1.30% [95%置信区间:1.11 - 1.50],ESBL-EC为0.97% [95%置信区间:0.80 - 1.14],ESBL-KP为0.27% [95%置信区间:0.18 - 0.36],与护理级别无关。正如预期的那样,多重耐药菌的现患率取决于护理级别和病房类型。总体现患率在重症监护病房最高,内科病房的现患率相比外科病房显著较高。所有三级护理机构都配备了自己的感染控制护士,而二级和一级护理医院只有约70%配备了。令人惊讶的是,在参与调查的10家三级护理机构中有两家既没有内部也没有外部的感染控制医生。

讨论

本次调查涵盖了德国各地56家医院的13000多名患者,调查的患者数量是第一次调查的三倍多,因此不仅增加了关于新出现的医院病原体流行病学的有价值信息,也有助于提高德国对抗菌药物耐药性问题的认识。报告的现患率似乎与前一次调查及其他已发表调查的结果相当。一些医院报告称根本没有感染控制人员。这一说法与本期发表的另一项调查结果一致。

相似文献

1
One-day point prevalence of emerging bacterial pathogens in a nationwide sample of 62 German hospitals in 2012 and comparison with the results of the one-day point prevalence of 2010.2012年德国62家医院全国性样本中新兴细菌病原体的一日点患病率及与2010年一日点患病率结果的比较。
GMS Hyg Infect Control. 2013 Apr 29;8(1):Doc12. doi: 10.3205/dgkh000212. eCollection 2013.
2
[Multidrug-resistant organisms and C. difficile in Munich acute-care clinics: Results from a point prevalence study of clinical routine data].[慕尼黑急症护理诊所中的多重耐药菌与艰难梭菌:临床常规数据现况调查结果]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Nov;58(11-12):1306-13. doi: 10.1007/s00103-015-2248-9.
3
Epidemiology of multidrug resistant bacterial organisms and Clostridium difficile in German hospitals in 2014: Results from a nationwide one-day point prevalence of 329 German hospitals.2014年德国医院多重耐药菌及艰难梭菌的流行病学:来自德国329家医院全国范围一日现患率调查的结果
BMC Infect Dis. 2016 Sep 2;16(1):467. doi: 10.1186/s12879-016-1756-z.
4
One-day point prevalence of emerging bacterial pathogens in four secondary and five tertiary care German hospitals - results from a pilot study of the German Society for Hospital Hygiene (Deutsche Gesellschaft für Krankenhaushygiene, DGKH).德国四家二级医院和五家三级医院新出现的细菌病原体的单日点患病率——德国医院卫生协会(Deutsche Gesellschaft für Krankenhaushygiene, DGKH)一项试点研究的结果。
GMS Krankenhhyg Interdiszip. 2011;6(1):Doc20. doi: 10.3205/dgkh000177. Epub 2011 Dec 15.
5
Increase of patients co-colonised or co-infected with methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium or extended-spectrum β-lactamase-producing Enterobacteriaceae.耐甲氧西林金黄色葡萄球菌、万古霉素耐药粪肠球菌或产超广谱β-内酰胺酶肠杆菌科细菌的患者共同定植或合并感染的增加。
Infection. 2011 Dec;39(6):501-6. doi: 10.1007/s15010-011-0154-0. Epub 2011 Jun 28.
6
Regional trends in multidrug-resistant infections in German intensive care units: a real-time model for epidemiological monitoring and analysis.德国重症监护病房中多重耐药感染的区域趋势:一种用于流行病学监测和分析的实时模型。
J Hosp Infect. 2009 Nov;73(3):239-45. doi: 10.1016/j.jhin.2009.07.017. Epub 2009 Oct 4.
7
Multi-level analysis of bacteria isolated from inpatients in respiratory departments in China.对中国呼吸内科住院患者分离出的细菌进行的多层次分析。
J Thorac Dis. 2018 May;10(5):2666-2675. doi: 10.21037/jtd.2018.04.46.
8
Colonization of skilled-care facility residents with antimicrobial-resistant pathogens.熟练护理机构居民对抗菌药物耐药病原体的定植。
J Am Geriatr Soc. 2001 Mar;49(3):270-6. doi: 10.1046/j.1532-5415.2001.4930270.x.
9
Prevalence of antibiotic-resistant organisms in Canadian Hospitals. Comparison of point-prevalence survey results from 2010, 2012, and 2016.加拿大医院抗生素耐药菌的流行情况。2010 年、2012 年和 2016 年的时点患病率调查结果比较。
Infect Control Hosp Epidemiol. 2019 Jan;40(1):53-59. doi: 10.1017/ice.2018.279. Epub 2018 Nov 5.
10
Differences in infection control and diagnostic measures for multidrug-resistant organisms in the tristate area of France, Germany and Switzerland in 2019 - survey results from the RH(E)IN-CARE network.2019 年法国、德国和瑞士三国交界地区多药耐药菌感染控制和诊断措施的差异 - RH(E)IN-CARE 网络的调查结果。
Swiss Med Wkly. 2021 Mar 1;151:w20454. doi: 10.4414/smw.2021.20454.

引用本文的文献

1
Vancomycin-resistant enterococci (VRE) in hospital settings across European borders: a scoping review comparing the epidemiology in the Netherlands and Germany.跨越欧洲边界的医院环境中的万古霉素耐药肠球菌(VRE):一项比较荷兰和德国流行病学的范围综述。
Antimicrob Resist Infect Control. 2023 Aug 12;12(1):78. doi: 10.1186/s13756-023-01278-0.
2
High prevalence of multidrug-resistant Gram-negative bacteria carriage in children screened prospectively for multidrug resistant organisms at admission to a paediatric hospital, Hamburg, Germany, September 2018 to May 2019.2018 年 9 月至 2019 年 5 月,德国汉堡一家儿童医院对入院患儿进行了前瞻性筛查,发现耐多药革兰氏阴性菌携带率较高。
Euro Surveill. 2022 Apr;27(15). doi: 10.2807/1560-7917.ES.2022.27.15.2001567.
3

本文引用的文献

1
Questionnaire-based survey on structural quality of hospitals and nursing homes for the elderly, their staffing with infection control personal, and implementation of infection control measures in Germany.基于问卷调查的德国医院和养老院的结构质量、感染控制人员配备及感染控制措施实施情况的调查。
GMS Hyg Infect Control. 2013 Apr 29;8(1):Doc11. doi: 10.3205/dgkh000211. eCollection 2013.
2
[Report of the third meeting of the coordinators of the regional MRP networks in Germany on 15 and 16 December 2011 at the Robert Koch Institute].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Nov;55(11-12):1474-82. doi: 10.1007/s00103-012-1553-9.
3
[Awareness, knowledge and responsibility].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Nov;55(11-12):1361-2. doi: 10.1007/s00103-012-1561-9.
Epidemiology of multidrug resistant bacterial organisms and Clostridium difficile in German hospitals in 2014: Results from a nationwide one-day point prevalence of 329 German hospitals.2014年德国医院多重耐药菌及艰难梭菌的流行病学:来自德国329家医院全国范围一日现患率调查的结果
BMC Infect Dis. 2016 Sep 2;16(1):467. doi: 10.1186/s12879-016-1756-z.
4
Intestinal Carriage of Carbapenemase-Producing Organisms: Current Status of Surveillance Methods.产碳青霉烯酶生物体的肠道携带情况:监测方法的现状
Clin Microbiol Rev. 2016 Jan;29(1):1-27. doi: 10.1128/CMR.00108-14.
5
Improving hospital hygiene to reduce the impact of multidrug-resistant organisms in health care--a prospective controlled multicenter study.改善医院卫生状况以降低医疗保健中多重耐药菌的影响——一项前瞻性对照多中心研究。
BMC Infect Dis. 2015 Oct 22;15:441. doi: 10.1186/s12879-015-1184-5.
6
Adult vaccination.成人疫苗接种。
Hum Vaccin Immunother. 2015;11(1):150-5. doi: 10.4161/hv.35858. Epub 2014 Nov 1.
7
How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?我们如何利用治疗药物监测来改善重症患者严重感染的治疗效果?
BMC Infect Dis. 2014 Nov 28;14:288. doi: 10.1186/1471-2334-14-288.
4
Cost-analysis of PCR-guided pre-emptive antibiotic treatment of Staphylococcus aureus infections: an analytic decision model.基于聚合酶链反应(PCR)指导的金黄色葡萄球菌感染预防性抗生素治疗的成本分析:一个分析决策模型。
Eur J Clin Microbiol Infect Dis. 2012 Nov;31(11):3065-72. doi: 10.1007/s10096-012-1666-y. Epub 2012 Jun 15.
5
Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition.医院获得性多重耐药铜绿假单胞菌感染的成本。
BMC Health Serv Res. 2012 May 23;12:122. doi: 10.1186/1472-6963-12-122.
6
The project HICARE: cross-sectoral action alliance against multi-resistant pathogens.“关爱健康”项目:跨部门抗击多重耐药病原体行动联盟。
GMS Krankenhhyg Interdiszip. 2011;6(1):Doc25. doi: 10.3205/dgkh000182. Epub 2011 Dec 15.
7
One-day point prevalence of emerging bacterial pathogens in four secondary and five tertiary care German hospitals - results from a pilot study of the German Society for Hospital Hygiene (Deutsche Gesellschaft für Krankenhaushygiene, DGKH).德国四家二级医院和五家三级医院新出现的细菌病原体的单日点患病率——德国医院卫生协会(Deutsche Gesellschaft für Krankenhaushygiene, DGKH)一项试点研究的结果。
GMS Krankenhhyg Interdiszip. 2011;6(1):Doc20. doi: 10.3205/dgkh000177. Epub 2011 Dec 15.
8
Long-term clinical and economic benefits associated with the management of a nosocomial outbreak resulting from extended-spectrum beta-lactamase-producing Klebsiella pneumoniae.产超广谱β-内酰胺酶肺炎克雷伯菌医院感染暴发的管理所带来的长期临床和经济效益。
Crit Care Med. 2011 Dec;39(12):2672-7. doi: 10.1097/CCM.0b013e31822827e0.
9
Nosocomial infections and multidrug-resistant organisms in Germany: epidemiological data from KISS (the Hospital Infection Surveillance System).德国的医院感染和多重耐药菌:来自 KISS(医院感染监测系统)的流行病学数据。
Dtsch Arztebl Int. 2011 Feb;108(6):87-93. doi: 10.3238/arztebl.2011.0087. Epub 2011 Feb 11.
10
[Economic aspects of the management and control of MRSA].[耐甲氧西林金黄色葡萄球菌管理与控制的经济层面]
Gesundheitswesen. 2009 Nov;71(11):771-6. doi: 10.1055/s-0029-1241891. Epub 2009 Nov 23.